Clinical evaluation of high-dose cytarabine and cisplatin in recurrent cervical carcinoma.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D001831:Body Temperature / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010976:Platelet Count; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D003561:Cytarabine; D003520:Cyclophosphamide; D003404:Creatinine; D002945:Cisplatin; D001663:Bilirubin